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Addendum
Muscle atrophy and diaphragmatic palsy are the clinical 
characteristics of spinal muscular 
atrophy with respiratory distress type 1 
(SMARD1), and are well represented in 
the neuromuscular degeneration (Nmd2J) 
mouse, modeling the juvenile form of 
SMARD1. Both in humans and mice 
mutations in the IGHMBP2 gene lead 
to motoneuron degeneration. We could 
previously demonstrate that treatment 
with a polyethylene glycol-coupled 
variant of IGF1 (PEG-IGF1) improves 
motor functions accompanied by reduced 
fiber degeneration in the gastrocnemius 
muscle and the diaphragm, but has no 
beneficial effect on motoneuron survival. 
These data raised the question which 
cell autonomous disease mechanisms 
contribute to dysfunction and loss of 
Ighmbp2-deficient motoneurons. An 
analysis of primary Ighmbp2-deficient 
motoneurons exhibited differentiation 
deficits such as reduced spontaneous 
Ca2+ transients and altered axon 
elongation, which was not compensated 
by PEG-IGF1. This points to an IGF1 
independent mechanism of motoneuron 
degeneration that deserves treatment 
approaches in addition to IGF1.
Introduction
Spinal muscular atrophy with 
respiratory distress type 1 (SMARD1) 
is a motoneuron disorder leading to 
early childhood death.1,2 The disease 
generally manifests in the first two years 
after birth with a characteristic distal 
muscle atrophy due to motoneuron loss 
and paralysis of the diaphragm.1,3,4 As 
a monogenetic disorder, SMARD1 is 
caused by mutations in the IGHMBP2 
(Immunoglobulin µ-binding protein 
2) gene on chromosome 11q13 which 
codes for an ATPase/helicase of the SF1 
superfamily.1,5 The helicase domain is 
the hot-spot for most of the mutations.2,6 
IGHMBP2 is predominantly localized 
in the cytoplasm of motoneurons where 
it is associated with ribosomes.6,7 The 
neuromuscular degeneration (Nmd2J) 
mouse, an Ighmbp2-deficient mouse 
model, represents the juvenile form 
of SMARD1 and is characterized 
by weakness and atrophy of the 
gastrocnemius muscle beginning in 
the second to third week after birth, 
preceding a massive myopathy of the 
diaphragm.8,9 In contrast to some 
SMA mouse models, neuromuscular 
junctions (NMJs) of skeletal muscles 
partially remain intact during disease 
progression, and neurotransmission 
appears unaffected as long as NMJs 
are maintained.9 These observations 
raised the question whether and which 
cell autonomous disease mechanisms in 
motoneurons cause dysfunction and loss 
in consequence of Ighmbp2 deficiency. 
We could previously show that a systemic 
application of a polyethylene glycol-
coupled IGF1 (PEG-IGF1)10 resulted in 
enhanced muscle strength accompanied 
by a significant improvement of muscle 
fiber calibers in Nmd2J mice.11 In 
addition, PEG-IGF1 supported axonal 
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sprouting at the nerve terminals of the 
gastrocnemius muscle leading to reduced 
denervation activity.11 Although PEG-
IGF1 stimulated the phosphorylation of 
the ribosomal protein S6 kinase in spinal 
cord of Nmd2J mice,11 the treatment 
did not increase motoneuron survival 
as recently reported for the progressive 
motoneuronopathy (pmn) mouse model.12 
These observations led to the hypothesis 
that Ighmbp2-deficient motoneurons 
may not be amenable to PEG-IGF1, 
and survival is a cell autonomous 
disease mechanism caused by Ighmbp2 
deficiency, which can’t be compensated 
by enhanced protein S6 kinase signaling. 
In order to investigate which specific 
disease mechanisms are caused by 
Ighmbp2 deficiency in motoneurons, 
we performed a morphological and 
functional analysis of isolated primary 
motoneurons from Ighmbp2-deficient 
embryonic spinal cord and investigated 
the effect of PEG-IGF1.
Reduced Frequency  
of Spontaneous Ca2+ Transients  
in Ighmbp2-Deficient 
Motoneurons
The complex phenotype of the Nmd2J 
mouse with atrophy of the gastrocnemius 
Figure 1. disturbed calcium homeostasis at distal axons and altered Cav2.2 accumulation at growth cones of Ighmbp2-deficient motoneurons on the 
synapse-specific laminin-221. (A) Spontaneous Ca2+ transients in isolated Ighmbp2-deficient motoneurons were markedly reduced in the growth cone 
compartment (Controls 0.30 ± 0.06 min-1, n = 22, vs. Ighmbp2 def. 0.09 ± 0.02 min-1, n = 73; u = 487, p** = 0.0047). The Ca2+ transient frequency in the cell 
body of Ighmbp2-deficient motoneurons was not affected (Controls 0.56 ± 0.10 min-1, n = 116, vs. Ighmbp2 def. 0.62 ± 0.11 min-1, n = 45; u = 2,152, P = 
0.08). (B) The quantitative analysis of Cav2.2 presence in Ighmbp2-deficient growth cones revealed a significant reduction (Controls 119.3 ± 3.5 a.u., n = 
92, vs. Ighmbp2 def. 77.1 ± 2.6 a.u., n = 106; u = 1,622, p*** < 0.001). In (B’, B”’) a decreased Cav2.2 accumulation in the protrusions of Ighmbp2-deficient 
growth cones is displayed, co-labeled with the active zone marker Bassoon (B”, B””). Analysis of Cav1.3 channels showed neither an altered distribution 
(C’, C”) nor reduced levels (C) in Ighmbp2-deficient motoneurons (Controls 22.7 ± 0.8 a.u., n = 76, vs. Ighmbp2 def. 21.7 ± 0.7 a.u., n = 81; u = 3,000, P = 
0.78). (D) no difference in signal intensity of synaptophysin was detected between Ighmbp2-deficient and control motoneurons (Controls 25.9 ± 1.6 a.u., 
n = 90, vs. Ighmbp2 def. 27.3 ± 1.4 a.u., n = 90; u = 3,552, P = 0.15). Synaptophysin was evenly distributed throughout the growth cone compartment and 
exhibited no difference regarding localization between Ighmbp2-deficient (D”’, D””) and control motoneurons (D’, D”). Single values were obtained 
from at least three different experiments. Statistical analysis was performed using mann-Whitney t test. Bars represent mean ± Sem, significance is indi-
cated by stars (p** < 0.01, p*** < 0.001, non-significance is indicated by n.s.).
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muscle and myopathy of the diaphragm 
poses the question of which cell 
autonomous disease mechanisms could 
correspond to their dysfunction. We have 
already shown that isolated SMA type I 
mouse motoneurons are characterized 
by reduced spontaneous Ca2+ transients 
caused by defective clustering of N-type-
specific Ca2+ channels (Ca
v
2.2), that 
results in altered axon elongation on the 
synapse-specific laminin-221.13 In order 
to examine affected cellular mechanisms 
under Ighmbp2 deficiency in more detail, 
we started a similar in vitro approach with 
isolated and enriched mouse motoneurons. 
Motoneurons from two week-old 
Ighmbp2-deficient and control embryos 
were cultured for five days in the presence 
of BDNF and CNTF (10 ng/ml, each) on 
laminin-221 to quantify the frequency 
of spontaneous Ca2+ transients via 
imaging studies. For the calcium imaging 
study cells were loaded with FURA-2, 
a ratiometric Ca2+-binding fluorescent 
dye. Measurements were performed by 
dual-excitation (340 and 380 nm) and 
single-emission ratio imaging. Images 
were acquired at a frequency of 1 Hz and 
exposure time was 10 ms. Spontaneous 
Ca2+ transients were recorded in growth 
cones and cell bodies over a time period 
of 5 to 7.5 min. The rate of spontaneous 
Ca2+ transients (events per min) in the cell 
body of Ighmbp2-deficient motoneurons 
was not changed, whereas in the axon 
terminals spontaneous Ca2+ elevations 
decreased markedly (Fig. 1A). We further 
investigated the distribution of Ca
v
2.2 
and Ca
v
1.3 channels in the growth 
cone of control and Ighmbp2-deficient 
motoneurons. Anti-Ca
v
2.2 stainings 
revealed a reduced accumulation of 
Ca
v
2.2 at the growth cone of Ighmbp2-
deficient motoneurons compared with 
control motoneurons (Fig.1B’ and 1B’’’). 
Membrane-localization was indicated 
by co-staining with Bassoon (Fig. 1, 
1B’’, and 1B’’’’). Immunostaining for 
Figure 2. Low doses of PeG-IGF1 do not compensate for the axon elongation defect in Ighmbp2-deficient motoneurons on the synapse-specific lam-
inin-221. In (A-C) the quantitative analyses of axon length, dendrite length, and growth cone size of Ighmbp2-deficient and control motoneurons are 
shown. (A) Isolated Ighmbp2-deficient motoneurons exhibited an altered axonal processing on laminin-221 (Controls 605.7 ± 13.4 µm, n = 585, vs. 
Ighmbp2 def. 780.9 ± 19.8 µm, n = 492; u = 104,000, p*** < 0.001). Representative images are shown in (A’, A”). (B) The dendrite length of Ighmbp2-
deficient motoneurons was comparable to the control situation (Controls 29.5 ± 0.8 µm, n = 292, vs. Ighmbp2 def. 28.4 ± 0.8 µm, n = 206; u = 30,010, P = 
0.97). In (C) a markedly growth cone size reduction is depicted (Controls 67.0 ± 5.2 µm2, n = 78, vs. Ighmbp2 def. 44.7 ± 2.4 µm2, n = 102; u = 2,739, p*** = 
0.0004). (D) The β-actin distribution and localization was disturbed in growth cones of Ighmbp2-deficient motoneurons (Controls 84.0 ± 3.0 a.u., n = 105, 
vs. Ighmbp2 def. 64.0 ± 2.1 a.u., n = 107; u = 3,486, p*** < 0.001). Representative images are shown in (D’, D”). In (E) the quantification of axon lengths 
from control and Ighmbp2-deficient motoneurons in the presence of CnTF (C), BdnF (B) (10 ng/ml, each), and PeG-IGF1 (I) (1 ng/ml), and PeG-IGF1 
(I) (1 ng/ml) alone is depicted (C+B+I: Controls 558.9 ± 14.6 µm, n = 375, vs. Ighmbp2 def. 711.7 ± 18.8 µm, n = 402; u = 55,050, p*** < 0.001. I: Controls 
498.4 ± 13.6 µm, n = 301, vs. Ighmbp2 def. 577.7 ± 22.7 µm, n = 190; u = 25,090, p* = 0.02). Single values were obtained from at least three different 
experiments. Statistical analysis was performed using mann-Whitney t test. Bars represent mean ± Sem, significance is indicated by stars (p* < 0.05, p*** 
< 0.001, non-significance is indicated by n.s.).
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Ca
v
1.3 that normally does not cluster in 
active zones in vivo14 exhibited no altered 
distribution or reduced signal intensity 
(Fig. 1C, 1C’, and 1C’’), indicating 
that the defect is specific for Ca
v
2.2 in 
axon terminals of Ighmbp2-deficient 
motoneurons. Reduced excitation in 
cultured motoneurons together with 
affected signal transduction of action 
potentials along the motor axons in 
Nmd2J mice9 raised the question whether 
synaptic vesicles are also reduced in the 
presynaptic compartment of Ighmbp2-
deficient primary motoneurons. 
We did not detect any difference 
concerning presence and distribution of 
synaptophysin immunoreactivity between 
isolated Ighmbp2-deficient and control 
motoneurons (Fig. 1D and 1D’–1D’’’’).
Low Doses of PEG-IGF1 do not 
Compensate for Altered Axon 
Elongation of Ighmbp2-Deficient 
Motoneurons on laminin-221
Based on our calcium imaging 
results and on our data from Smn-
deficient motoneurons13 we performed 
a morphological analysis of the 
differentiation behavior of Ighmbp2-
deficient motoneurons. Wild-type and 
Ighmbp2-deficient motoneurons were 
cultured on laminin-221 in the presence 
of CNTF and BDNF (10 ng/ml, each) 
and differentiation was analyzed by 
quantification of axon and dendrite 
lengths at DIV7, and growth cone sizes 
at DIV5. Ighmbp2-deficient mouse 
motoneurons showed enhanced axon 
elongation (Fig. 2A, 2A’, and 2A’’), 
whereas the dendrite length was unaffected 
(Fig. 2B). In addition to the altered axonal 
outgrowth, we also detected significant 
smaller growth cones corresponding 
to a microfilament deficit indicated by 
reduced β-actin presence in the growth 
cones of Ighmbp2-deficient motoneurons 
(Fig. 2C, 2D, 2D’, and 2D’’). Application 
of PEG-IGF1 (1 ng/ml) to the medium 
during the whole culture period did not 
modify the enhanced axon elongation 
of Ighmbp2 deficient motoneurons on 
laminin-221 (Fig. 2E). We have chosen 
1 ng/ml PEG-IGF1 for this long-term 
treatment as the optimal survival effect for 
one-week cultures of isolated motoneurons 
lies within the range of 1 ng/ml and 10 
ng/ml (data not shown).
Cell Autonomous Disease 
Mechanisms Observed in Primary 
Motoneuron Cultures Differ 
between Mouse Models for 
Motoneuron Disorders
Prolonged axonal elongation on 
laminin-221 of Ighmbp2-deficient 
motoneurons due to reduced frequency 
of Ca2+ transients reflects nerve cell 
autonomous disease mechanisms at 
a presymptomatic stage, similar to 
the results observed in studies with 
motoneurons deficient for Smn and its 
interaction partner hnRNPR, in mouse 
and zebrafish.13,15 Such kind of defects 
in axon elongation, corresponding to 
excitation disturbances are specific and 
are not seen in all mouse models for 
motoneuron diseases. They are observed 
in SMA and SMARD1 motoneurons, 
but e.g. not in isolated motoneurons 
from SOD1G93A mutant mice, a model 
for a familial form of amyotrophic lateral 
sclerosis.16 However, the pmn mouse is 
another model with differentiation defects 
in primary motoneurons. But the disease 
mechanisms differ insofar that reduced 
axon lengths on laminin-111 due to a 
defective microtubule assembly in pmn 
motoneurons can be fully compensated by 
external application of PEG-IGF1.12 Not 
only in cell culture, also in vivo, PEG-
IGF1 prevents pmn motoneurons from 
degeneration.12 These data ultimately 
argue for specific cell autonomous disease 
mechanisms corresponding to particular 
genetic dysfunctions in each mouse 
model.
Isolated motoneurons even from wild-
type mouse embryos behave differently 
under specific culture conditions (data 
not shown). Neurotrophic factors and 
matrix proteins are only two components 
that could influence the axonal outgrowth 
and the excitation of cultured primary 
motoneurons. As we already demonstrated 
for isolated motoneurons from a SMA 
type I mouse model, axonal extension and 
local excitation depend, among others, 
on the matrix protein.13 Thus one can’t 
draw conclusions to the axon elongation 
behavior in vivo from morphological and 
even functional studies with primary 
motoneurons. The influence of the 
neighboring non-neuronal tissue and 
the fast changing developmental stages 
during motoneuron maturation in vivo 
is far too high. However, differentiation 
behavior of enriched primary murine 
motoneurons from motoneuron disease 
models are a very important technical 
tool to understand altered cellular 
mechanisms, especially signaling 
pathways that might affect motoneuron 
development at very early symptomatic 
or even pre-symptomatic stages. Enriched 
primary motoneurons, albeit they do 
not completely represent the in vivo 
situation, are useful to investigate cellular 
dysfunctions in more detail. The more we 
know about cell-specific dysregulations at 
very early disease stages, the higher the 
possibility to identify the mechanisms 
that could bypass the affected cellular 
targets in the face of potential therapeutic 
strategies.
PEG-IGF1 Induced Akt/protein 
S6 Kinase Pathway Activation 
has no Compensatory Effect in 
Motoneurons when Ighmbp2 is 
Missing
As it is currently known, PEG-IGF1 
stimulates the Akt/protein S6 kinase 
phosphorylation in isolated motoneurons 
and in spinal cord tissue from Nmd2J 
mice, but does not prevent motoneuron 
degeneration in vivo11 and differentiation 
defects in vitro (Fig. 2E). This is in 
contrast to the observed positive effects 
in striated muscles of Nmd2J mice. Four-
week treatment with 0.05 mg/kg PEG-
IGF1 delayed muscle fiber degeneration, 
both in the gastrocnemius muscle and 
the diaphragm.11 One reason might be 
the “underdosed” treatment, as already 
discussed by Krieger et al.11 as doses 
higher than 0.05 mg/kg were not tolerated 
by the Nmd2J mouse. Higher doses were 
needed to obtain a beneficial effect on 
motoneuron survival in other mouse 
models for motoneuron degeneration 
such as the pmn mouse.12 However, with 
regard to our in vitro data, it is even 
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more likely that Ighmbp2 deficiency 
places a gap in the IGF1 receptor/Akt/
p70S6K signaling pathway. p70S6K is 
discussed to be an important factor for 
translation initiation.17 The ability for 
Akt/p70S6K stimulation in embryonic 
motoneurons indicates that Ighmbp2 
is acting downstream of the p70S6K 
signaling pathway or acts completely 
independent from the Akt/mTOR/
p70S6K pathway. Ighmbp2 is a ribosome 
associated ATPase/helicase mainly 
localized to the cytoplasm and subjected 
to unwinding RNAs.6 The specific role 
of Ighmbp2 remains to be elucidated, but 
possible scenarios could be discussed as 
follows: (1) Ighmbp2 assists the proper 
orchestration of ribosome-assembly, (2) 
the helicase could be involved in the 
regulation of tRNA pathways as already 
postulated,7 or (3) Ighmbp2 plays a role 
in translation initiation via processing 
of mRNAs by unwinding secondary 
structures, and/or removing microRNAs 
or bound proteins. Especially the defective 
translation of mRNAs that encode 
for proteins with functions for axon 
maintenance, such as axonal transport or 
transmission of action potentials along 
motor axons, could cause motoneuron 
and motor axon degeneration. Axonally 
transported mRNAs are, e.g., those that 
encode for cytoskeletal proteins such as 
Tau18,19 and neurofilament.20 Proteins 
that are important for action potential 
transmission are, among others, sodium 
and potassium channels.
Excitation in Motoneurons 
Affected by Ighmbp2 Deficiency
Developing motoneurons in 
vertebrates exhibit spontaneous calcium 
elevations while they are targeting 
striated muscles.21-23 In isolated embryonic 
motoneurons from rodents, spontaneous 
excitation is preserved and observed 
in axons and axonal growth cones.13,24 
Spontaneous Ca2+ transients in neurons 
contribute to presynaptic differentiation 
via interaction with matrix proteins.13,25,26 
Numerous publications have already 
reported the impact of Smn deficiency 
on excitation and Ca2+ gating channels in 
neurons and glia cells from mouse models 
of proximal spinal muscular atrophy 
(SMA).13,24,27-30 As we described herein, 
spontaneous excitation disturbances 
were also observed in Ighmbp2-deficient 
motoneurons (Fig. 1A) which led to 
axonal elongation defects (Fig. 2A). 
However, not only in vitro but also in vivo, 
variabilities in excitation were monitored.9 
Electrophysiological recordings at the 
affected LAL muscle of Nmd2J mice showed 
a higher probability for “failures,” stimuli 
that failed to evoke postsynaptic responses 
during nerve repetitive stimulation, but 
with preserved EPP amplitudes.9 We, 
therefore, conclude from these findings 
that the failures were not due to a defect in 
synaptic vesicle availability, in Ca2+ entry, 
or in the release machinery, and that axonal 
degeneration is hence independent from 
those neurotransmission impairments.9 
This encouraged us to postulate that 
defects or deficits of ion channels, such 
as potassium or sodium channels, may 
also have an impact on motor axon 
dysfunction and degeneration. As already 
reported, a member of the voltage 
gated sodium channel family termed 
Na
v
1.9 supports differentiation in early 
motoneurons via axonal excitation.24,31 We 
postulate that Na
v
1.9 in the adult mouse 
has an impact on rapid propagation of 
action potentials along the axon, and that 
a deficit or defect of this channel might 
impair axonal stability independent 
from neurotransmission. The detailed 
analysis on localization and function of 
Na
v
1.9 in the Nmd2J mouse would reveal 
first hints whether sodium channels are 
affected targets in an Ighmbp2-deficient 
environment.
Affected Microfilaments in 
Ighmbp2-Deficient Motoneurons
The observed excitability disturbances 
in vitro and in vivo9 could be a primary 
or secondary effect due to Ighmbp2 
deficiency. As discussed and postulated by 
others, Ighmbp2/IGHMBP2 could play a 
pivotal role in cellular protein biosynthesis 
mechanisms.6,7 We already know from our 
studies that the IGF1/Akt/p70S6K pathway 
is still inducible in Ighmbp2-deficient 
motoneurons,11 which draw the attention 
to other signaling pathways important 
for the microfilament orchestration. We 
observed a reduction in β-actin protein, 
suggesting that the translation of this 
mRNA is affected when Ighmbp2 is 
missing. As local protein biosynthesis 
in different cellular compartments 
plays a role especially in axon guidance 
mechanisms,32 Ighmbp2 deficiency might 
diminish the recognition of guidance 
cue signaling. Shigeoka and Holt have 
summarized known guidance cues and 
their target mRNAs.32 β-actin mRNA 
is a very prominent target candidate for 
local protein synthesis, as Netrin133-37 
and the neurotrophic factors BDNF and 
NGF38,39 stimulate its local translation. 
These results are obtained from retinal 
ganglia cells, hippocampal, cortical, and 
spinal neurons. The wide abundance 
of actin mRNA in neurons and the 
indispensability of microfilaments in 
the orchestration of different cellular 
compartments, especially the proper 
localization of transmembrane proteins 
such as receptors or ion channels, arises 
the hypothesis that Ighmbp2-deficient 
motoneurons do not correctly recognize 
and/or process signaling mediated by 
guidance cues or neurotrophic factors. 
This disability could affect motoneuron 
survival, differentiation, proper reaching 
of the target tissue, and subsequent 
maturation. Insufficient maturation 
of neuromuscular endplates has been 
already described in the mouse model 
for SMARD1,9,40 thus pointing to a 
mechanism which affects neuromuscular 
maturation, but might also compromise 
other cellular compartments.
Conclusion
Our in vitro data showed that 
Ighmbp2 deficiency causes altered cell 
autonomous mechanisms which lead to 
affected differentiation behavior. The 
application of 1 ng/ml of PEG-IGF1 had 
no modifying effect on these alterations. 
These results underline our in vivo data 
from the Nmd2J mouse.11 Four-week 
treatment with PEG-IGF1 activates the 
Akt/p70S6K pathway, but does not result 
in increased motoneuron survival.11 This 
raises the question of which cellular targets 
are affected by Ighmbp2 deficiency. Beside 
www.landesbioscience.com Rare diseases e29415-6
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the identification of targeted RNAs 
and their proteins in Ighmbp2-deficient 
motoneurons, the specific examination 
of other survival and differentiation 
supporting mechanisms, such as protein 
biosynthesis or RNA/protein degradation, 
would highly improve the understanding 
of motoneuron degeneration in SMARD1. 
The analysis of affected and unaffected 
cellular mechanisms will facilitate the 
identification of signaling pathways, 
which compared with IGF1 signaling 
better bypass cellular dysfunctions caused 
by Ighmbp2 deficiency.
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